Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche Medical Dialogues Bureau25 Nov 2019 9:00 AM ISTMedian overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
Roche drug cocktail doubles chance of holding lung cancer at bay Ruby Khatun Khatun9 Dec 2017 9:45 AM ISTZURICH: Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease...
Bristols drug cocktail cuts kidney cancer death risk 37 percent Ruby Khatun Khatun14 Sept 2017 9:25 AM ISTMADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...